Last updated: February 26, 2026
What is the drug associated with NDC 31722-0096?
NDC 31722-0096 corresponds to Sepofarsen (QR-110), developed by ProQR Therapeutics. Sepofarsen aims to treat Leber Congenital Amaurosis (LCA), a rare inherited retinal disease caused by mutations in the CEP290 gene.
Market Overview
Target Population and Incidence
LCA affects approximately 2,500 to 3,000 patients in the United States. The disease manifests early in life with severe visual impairment or blindness. CEP290 mutations account for about 20% of LCA cases, narrowing the treatable population to roughly 500 to 600 patients in the U.S. (source: Orphanet).
Competitive Landscape
Currently, no FDA-approved gene therapy or pharmacologic treatment exists specifically for CEP290-related LCA. Off-label use and supportive therapies dominate. Emerging gene-specific therapies are in clinical trials, but none has received approval.
Regulatory Status
Sepofarsen received the FDA's orphan drug designation, facilitating development incentives. Clinical trials are ongoing, with preliminary data indicating targeted vision improvements in a subset of patients.
Market Potential
| Parameter |
Details |
| Target Patients (US) |
500–600 (CEP290-LCA subset) |
| Market Penetration (Year 1) |
10%–15% based on early enrollment and prescriber acceptance |
| Pricing (Estimated) |
$375,000–$450,000 per dose, based on similar rare ophthalmic drugs |
| Treatment Regimen |
One-time intravitreal injection annually or biannually |
Pricing Benchmarks
- Luxturna (voretigene neparvovec) set at approximately $850,000 per eye.
- Vitrine's gene therapies hover around $200,000–$300,000 per dose.
Sepofarsen's proposed price reflects its early developmental stage and targeted, one-time gene-modulating mechanism.
Revenue Projections
| Year |
Assumed Patients Treated |
Revenue (USD) |
Notes |
| 2024 |
50–100 |
$18.75M–$45M |
Early market entry |
| 2025 |
150–250 |
$56.25M–$112.5M |
Growing awareness and approvals |
| 2026 |
300–400 |
$112.5M–$180M |
Increasing adoption |
Estimates assume 25–50% of the target CEP290-LCA population receiving treatment after approval.
Price Sensitivity and Market Dynamics
- Price elasticity remains uncertain; payers may negotiate discounts.
- Reimbursement depends on outcomes, patient access programs, and applicant willingness to demonstrate value.
- Payer approval is driven by the unmet need, disease severity, and lack of alternatives.
Risks and Barriers
- Clinical efficacy: Early data is promising but limited.
- Reimbursement: Price negotiations could lower revenue projections.
- Manufacturing: Complex gene delivery systems could limit scalability.
- Regulatory hurdles: Pending approval timelines could delay market entry.
Key Takeaways
- The product targets a narrow patient population with high unmet need.
- Estimated launch price ranges from $375,000 to $450,000.
- Total U.S. market size could reach $180 million annually post-adoption.
- R&D and regulatory timelines remain a primary risk factor.
- Market entry could reshape the landscape of inherited retinal disease treatments.
Frequently Asked Questions
What is the expected timeline for commercialization?
Clinical trials are ongoing, with potential FDA approval as early as 2024–2025, depending on trial outcomes and review processes.
How does the drug's price compare to similar therapies?
Sepofarsen's projected price per dose is lower than Luxturna's $850,000 but within the range of emerging gene therapies targeting rare diseases.
Who are the main competitors?
No approved therapies exist for CEP290-LCA. Competitors include pipeline candidates and supportive care providers, but none with an approved, targeted gene therapy.
What factors could influence reimbursement levels?
Clinical efficacy, durability of effect, manufacturing costs, and patient outcomes data determine reimbursement negotiations.
Is this an attractive investment?
The high unmet need, limited competition, and potential for premium pricing support investment; however, regulatory and clinical risks remain significant.
References
- Orphanet. Leber Congenital Amaurosis. (2023). Retrieved from https://www.orpha.net
- ProQR Therapeutics. Sepofarsen clinical trial updates. (2023). Retrieved from https://www.proqr.com
- Food and Drug Administration. Orphan Drug Designations. (2022). Retrieved from https://www.fda.gov
- Biopharma Market Data. Rare Ophthalmology Drugs. (2022). [Company Reports]
- Pricing and reimbursement estimate sources. (2023). [Market Analysis Reports]
